Last reviewed · How we verify
Taurolidine and Heparin
Taurolidine and Heparin is a Anti-coagulant [EPC] Small molecule drug developed by CorMedix. It is currently FDA-approved. Also known as: DefenCath®.
At a glance
| Generic name | Taurolidine and Heparin |
|---|---|
| Also known as | DefenCath® |
| Sponsor | CorMedix |
| Drug class | Anti-coagulant [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
- Hemodialysis catheter malfunction
- Hemorrhage/bleeding
- Nausea
- Vomiting
- Dizziness
- Musculoskeletal chest pain
- Thrombocytopenia
Serious adverse events
- Serious adverse reactions (overall)
- Adverse reactions leading to death
- Adverse reactions leading to discontinuation
- Heparin-Induced Thrombocytopenia
- Drug Hypersensitivity
- Hypocalcemia
- Dysgeusia
- Paresthesia
Key clinical trials
- Efficacy of Taurolidine Containing Lock Solution for Prevention of Central Venous Catheter Infection in ICU Patients (NA)
- Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC) (PHASE3)
- Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age (PHASE4)
- Antimicrobial Locks for Hemodialysis Catheter Infections (PHASE2)
- Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection (PHASE3)
- Expanded Access Program for Patients At Risk for Catheter-related Infections Who Are Not Eligible for DefenCath® Clinical Trials
- Central Line-associated Bloodstream Infection Prevention Using TauroLock-Hep100 in Pediatric Oncology Patients. (NA)
- Taurolock Hep 500 Versus Unfractionated Heparin as Anti-inflammatory in Hemodialysis Catheters. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Taurolidine and Heparin CI brief — competitive landscape report
- Taurolidine and Heparin updates RSS · CI watch RSS
- CorMedix portfolio CI
Frequently asked questions about Taurolidine and Heparin
What is Taurolidine and Heparin?
Taurolidine and Heparin is a Anti-coagulant [EPC] drug developed by CorMedix.
Who makes Taurolidine and Heparin?
Taurolidine and Heparin is developed and marketed by CorMedix (see full CorMedix pipeline at /company/cormedix).
Is Taurolidine and Heparin also known as anything else?
Taurolidine and Heparin is also known as DefenCath®.
What drug class is Taurolidine and Heparin in?
Taurolidine and Heparin belongs to the Anti-coagulant [EPC] class. See all Anti-coagulant [EPC] drugs at /class/anti-coagulant-epc.
What development phase is Taurolidine and Heparin in?
Taurolidine and Heparin is FDA-approved (marketed).
What are the side effects of Taurolidine and Heparin?
Common side effects of Taurolidine and Heparin include Hemodialysis catheter malfunction, Hemorrhage/bleeding, Nausea, Vomiting, Dizziness, Musculoskeletal chest pain. Serious adverse events: Serious adverse reactions (overall), Adverse reactions leading to death, Adverse reactions leading to discontinuation, Heparin-Induced Thrombocytopenia.
Related
- Drug class: All Anti-coagulant [EPC] drugs
- Manufacturer: CorMedix — full pipeline
- Also known as: DefenCath®
- Compare: Taurolidine and Heparin vs similar drugs
- Pricing: Taurolidine and Heparin cost, discount & access